Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives

Pharmacotherapy

Volumn 29, Issue 8, 2009, Pages 924-929

  Kearney, Brian P ^a   Mathias, Anita ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Drug interaction; Oral contraceptive; Pharmacokinetics; Tenofovir; Tenofovir DF; Tenofovir disoproxil fumarate

Indexed keywords

DEACETYL NORGESTIMATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; NORGESTIMATE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; RHINITIS; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADENINE; ADULT; ANTI-HIV AGENTS; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NORGESTREL; PHOSPHONIC ACIDS;

EID: 68149160026     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.8.924     Document Type: Article

References (20)

1. The Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization. AIDS epidemic update: December 2007. Available from http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf. Accessed January 2009.
2. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18:472-484 (Pubitemid 20183889)
3. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46:111-116 (Pubitemid 28342780)
4. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843
5. National Institutes of Health. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents, November 3, 2008. Available from http://AIDSinfo.nih.gov. Accessed January 2009.
6. Louie M, Hogan C, Hurley A, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 2003;17:1151-1156 (Pubitemid 36667757)
7. Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003;139(5 pt 1):313-320 (Pubitemid 38124586)
8. Gallant JE, De Jesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260
9. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006;43:535-540 (Pubitemid 44885619)
10. Gilead Sciences. Viread (tenofovir disoproxil fumarate) U.S. prescribing information. Foster City, CA; 2006.
11. Hawkins T, Veikley W, St Claire RL III, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005;39:406-411 (Pubitemid 41003784)
12. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43:595-612. (Pubitemid 38951802)
13. Saag MS. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis 2006;42:126-131
14. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products: general considerations (revision 1). Rockville, MD: U.S. Department of Health and Human Services, 2003.
15. Back DJ, Madden S, Orme ML. Gastrointestinal metabolism of contraceptive steroids. Am J Obstet Gynecol 1990;163(6 pt 2):2138-2145
16. Madden S, Back DJ. Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro. J Steroid Biochem Mol Biol 1991;38:497-503.
17. Shenfield GM, Griffin JM. Clinical pharmacokinetics of contraceptive steroids: an update. Clin Pharmacokinet 1991;20:15-37.
18. Newburger J, Goldzieher JW. Pharmacokinetics of ethynyl estradiol: a current view. Contraception 1985;32:33-44. (Pubitemid 15227617)
19. Orme ML, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet 1983;8:95-136.
20. Alton KB, Hetyei NS, Shaw C, Patrick JE. Biotransformation of norgestimate in women. Contraception 1984;29:19-29.